Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Although plenty of advancements in medical science have allowed humans to reduce the health impact of diabetes, a cure is still far off in the distance. With the advent of CRISPR, however, researchers are now much closer to finding effective treatment methods that will completely cure diabetics. These include stem cell implants and skin grafts.
One of the biggest challenges to combating both type-1 and type-2 diabetes is the matter of insulin production. Once those sensors in the body get broken, either not enough insulin is produced or the hormone itself becomes difficult for the body to process, Futurism reports. Thanks to certain advancements in gene-editing, however, these may not be much of a problem in the future.
On one hand, there’s the stem cell-based PEC-Direct implant that is made by the company ViaCyte. Similar in size to credit cards, these implants are basically meant to supplement the pancreas cells that the immune system has destroyed in type-1 patients. As the implants mature, they release insulin as needed, which would remove the necessity of injecting the hormone into the body.
The other method is a skin graft that was developed by researchers at the University of Chicago. Created using CRISPR, the scientists were able to create an artificial layer of skin that would promote insulin release, which would then manage the symptoms of diabetes. This particular method is initially intended for type-2 cases, but its scope can go beyond the disease.
Using the skin graft on lab mice, the researchers noticed marked improvements regarding symptoms associated with diabetes. Human trials are not on the table yet, however.
According to the researchers that worked on the study, it could also be applied to other kinds of metabolic conditions and genetic diseases that are caused by issues related to hormone production. It’s worth noting that, while this is not exactly curing diabetes, it does help improve the understanding of scientists when it comes to the potential solutions regarding skin graft.
